Thursday, May 19, 2022

Power Alley -- But... Tardy: Amgen's Lobby Spend Up Sharply In Q1 2022, Like Pfizer & Merck Before It...


Yes, I am about a month overdue with this report -- the raw data from the Congressional disclosure forms has been available since April 20. I apologize. [And, since Pfizer is significantly larger on a market cap basis, than either of the others mentioned, we would expect its spend would be larger -- but it is out-sized, still -- compared to its size advantage over the two.]

And you may compare the below to the ones I did on Pfizer here -- and Merck, here, each for the same period as the below. Enjoy -- but that's a. . . lot of. . . scratch, for just one fourth of a one year:

. . .H.R. 3, Prescription drug pricing issues;
H.R. 19 Lower Costs, More Cures Act of 2021;
H.R. 5260 Reduced Costs and Continued Cures Act;
H.R.5376, Build Back Better Act;
S2891 Restoring America Invents Act, patent thickets/product hopping;
HR 4521 Unites States Innovation and Competition Act
of 2021 Issues related to FTC;
Biosimilars reimbursement issues, no specific bill:
Supply Chain Issues, no specific bill;
Issues related to clinical trial diversity, HR 6584 DEPICT Act;
HR5030 DIVERSE Trials Act;
Issues related to biodefense issues, S3799 PREVENT Pandemics Act;
Issues related to cardiovascular disease awareness, no specific bill;
H.R. 5801 HELP Copays Act;
Issues related to patient affordability issues, including copay cards, copay accumulators, National Benefit Payment Parameters FDA Issues; User Fee Reauthorization (no specific bill);
H.R. 6963, the Accelerated Approval Integrity Act of 2022;
H.R. 7047, a bill to amend Title III of the Public Health Service Act with respect to the determination by the Secretary regarding certain biosimilar application elements, and for other purposes;
H.R. 6000, the Cures 2.0 Act; and
H.R. 7008, the Pre-Approval Information Exchange Act (among other matters). . . .


Now you know -- onward, grinning at the idea of an "over/under" bet -- measured in weeks, before Martin Shkreli sees his halfway house placement revoked, due to a terms of monitored release violation. We shall see. I hope he's learned some. . . self-control, and self-reflection, while away.

नमस्ते

2 comments:

Anonymous said...

More space science fun: https://www.cnn.com/2022/05/18/world/nasa-voyager-1-issue-scn/index.html

Can you say 'Star Trek, the Motion Picture'; Vger---

condor said...

This is. . . E X A C T L Y ! what crossed my mind, as well -- it is clear the Universe has a well-developed sense of humor. Or. . . irony, at least. What a clunky but fun flick!

Do see above -- your riff, now immortalized -- for eternity. Hah!

https://shearlingsplowed.blogspot.com/2022/05/it-takes-two-days-for-light-to-go-round.html

Namaste. . . great stuff!